Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Noting that VHB937 binds with equal affinity to the soluble and transmembrane forms of the receptor, Sovago attributed the rise of sTREM2 to longer half-life of the antibody-bound form. She pointed ...

Noting that VHB937 binds with equal affinity to the soluble and transmembrane forms of the receptor, Sovago attributed the rise of sTREM2 to longer half-life of the antibody-bound form. She pointed ...

For treating brain diseases, the bispecific antibodies from Grabody contain a domain designed to bind to insulin-like growth factor 1 receptor (IGF1R), a receptor that transports proteins across ...

IGF1R is a transmembrane receptor found on the BBB, a semi-permeable membrane between the blood and the network of fluid-filled spaces and connective tissue that surrounds the brain and is ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of haematological malignancies and has demonstrated efficacy in early trials for solid tumours, neurological and ...

Background: Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has proven effective ... changing CAR internalization and recycling is a promising approach. The transmembrane domain is the ...

However, the mechanisms that orchestrate the functions of mononuclear phagocytes remain poorly understood. TREM2 (triggering receptor on myeloid cells 2) has been shown to be crucial for the ...

1 Affiliated Hospital of Shandong Second Medical University, Weifang, China 2 Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China Chimeric antigen receptor natural ...